-
1
How nanotechnology and biomedical engineering are supporting the identification of predictive biomarkers in neuro-oncology
Published 2018“…The field of neuro-oncology is rapidly progressing and internalizing many of the recent discoveries coming from research conducted in basic science laboratories worldwide. …”
Journal article -
2
Brain white matter fibre tracts: a review of functional neuro-oncological relevance
Published 2017“…<p>State-of-the-art glioma treatment aims to maximise neuro-oncological benefit while minimising losses in quality of life. …”
Journal article -
3
-
4
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
Published 2002“…The prospective multicenter NOA-03 trial, conducted by the Neuro-Oncology Working Group (NOA) of the German Cancer Society, was initiated to define the feasibility and efficacy of single-agent high-dose methotrexate therapy without concomitant radiotherapy in immunocompetent patients with primary central nervous system lymphoma. …”
Journal article -
5
The role of [18F]fluorodopa positron emission tomography in grading of gliomas
Published 2022“…</p> <p><strong>Results:</strong> In 2016 the Response Assessment in Neuro-Oncology (RANO) and European Association for Neuro-Oncology (EANO) published recommendations on the clinical use of PET imaging in gliomas. …”
Journal article -
6
The influence of the α/β ratio on treatment time iso-effect relationships in the central nervous system
Published 2020“…It is important to establish if an α/β ratio of 2 Gy, the accepted norm for neuro-oncology iso-effect estimations, can be used.</p> <p><strong>Methods:</strong> The rat spinal cord irradiation data of Pop et al. provided ED50 values for radiation myelopathy for treatment times that varied from minutes to ∼6 days. …”
Journal article -
7
FUTURE-GB: functional and ultrasound-guided resection of glioblastoma – a two-stage randomised control trial
Published 2022“…There are multiple other surgical adjuncts available to the neuro-oncology surgeon. However, access to, and usage of these varies widely in UK practice, with limited evidence of their use. …”
Journal article